Taselisib

Taselisib is an orally bioavailable, selective inhibitor of phosphoinositide 3-kinase (PI3K) isoform p110α. It belongs to the class of PI3K inhibitors and has been investigated as a potential treatment for various cancers.

Mechanism of Action: Taselisib works by binding to and inhibiting the p110α subunit of PI3K. The PI3K pathway is involved in cell growth, proliferation, survival, and metabolism. The p110α isoform is frequently mutated or overexpressed in various cancers, contributing to uncontrolled cell growth. By inhibiting p110α, Taselisib aims to disrupt the PI3K signaling pathway, thereby suppressing tumor growth and inducing apoptosis (programmed cell death) in cancer cells.

Clinical Development: Taselisib has been studied in clinical trials for the treatment of different types of solid tumors, particularly breast cancer. Studies have evaluated Taselisib as a single agent and in combination with other anti-cancer therapies, such as hormone therapies in hormone receptor-positive breast cancer.

Adverse Effects: Like other PI3K inhibitors, Taselisib can cause a range of adverse effects. Common side effects observed in clinical trials include hyperglycemia (high blood sugar), diarrhea, rash, nausea, and fatigue.

Current Status: The development status of Taselisib may vary. It is recommended to consult current medical literature and regulatory databases for the most up-to-date information on its approval status and clinical use.